# Link bariatric and GLP-1 registries to cancer registries in every country that has both

Source: https://onco.cc/ideas/idea-nl-bariatric-cancer-registry-linkage/  
OnCo record `idea-nl-bariatric-cancer-registry-linkage` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Millions of people have had weight-loss surgery or now take weight-loss drugs. Linking those records to cancer registries would show, cancer by cancer, how much reversing obesity prevents, for almost no cost.

## Summary

Nordic registries and the Cleveland Clinic SPLENDID cohort show about a third fewer obesity-related cancers after bariatric surgery, but individual sites (oesophageal adenocarcinoma, colorectal, pancreatic) are underpowered, and the emerging GLP-1 receptor agonist data are from insurance claims with short follow-up. Most high-income countries have national bariatric surgery registries, complete cancer registries and prescription databases; a federated linkage with a common protocol would produce site-specific, sex-specific estimates, detect any unexpected harm (post-bariatric colorectal cancer, thyroid), and provide the counterfactual against which GLP-1 drugs can be judged.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Federated linkage across at least five countries will show site-specific reductions in cancer incidence after bariatric surgery that scale with weight loss maintained at five years, and GLP-1 receptor agonist users will show a similar gradient by cumulative exposure.
- Rationale: The exposure is common, the outcome registries exist, the analytic methods (target trial emulation) are mature, and randomised trials with cancer endpoints are a decade away. The data would inform both prevention policy and the design of any GLP-1 cancer trial.
- Proposed test: Common-protocol federated analysis (Sweden, Denmark, Finland, Scotland, Ontario, Israel) of bariatric surgery and GLP-1 receptor agonist exposure vs matched obese controls with cancer incidence by site as outcome; pre-registered, with results published within three years.
- Maturity: early-clinical
- Actor: data

## Sources

- Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019): https://doi.org/10.1001/jamainternmed.2019.0462

## Connected records

- ideas: [A trial of GLP-1 weight-loss drugs with cancer as the primary outcome](https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Bariatric surgery and cancer incidence](https://onco.cc/technologies/bariatric-surgery-cancer-incidence/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/)
- institutions: [Cleveland Clinic Taussig Cancer Institute](https://onco.cc/institutions/cleveland-clinic/), [Karolinska University Hospital](https://onco.cc/institutions/karolinska/)
- terms: [Obesity-related cancers (IARC list of 13)](https://onco.cc/terms/obesity-related-cancers/), [Real-world evidence](https://onco.cc/terms/real-world-evidence/)
- bottlenecks: [Data silos](https://onco.cc/bottlenecks/b-data-silos/), [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/), [Weak real-world evidence and registries](https://onco.cc/bottlenecks/b-real-world-evidence/)
- key papers: [Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval](https://onco.cc/key-papers/paper-gyawali-jama-intern-med/)

---
JSON: https://onco.cc/api/v1/entities/idea-nl-bariatric-cancer-registry-linkage.json